BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trialBNC210 Phase 2b PTSD trial on target for start in mid-2021 with final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback